Comparison of different stool tests for the detection of cancer of the colon;Vergleich verschiedener stuhltests zur detektion von neoplasien des kolon

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 14, 2005, Pages 872-877

  Vogel, T ^a   Driemel, C ^b   Hauser, A ^b   Hansmann, A ^b   Lange, S ^c   Jonas, M ^b   Moslein G ^b,d  

^a Abt Allgemein Viszeral /T   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d Universitatskliniku Dusseldorf   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; PYRUVATE KINASE; PYRUVATE KINASE M2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CHEMICAL ANALYSIS; COLON CANCER; COLONOSCOPY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMUNOLOGICAL PROCEDURES; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY;

AGED; BIOCHEMISTRY; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; FECES; FEMALE; GUAIAC; HUMANS; IMMUNOLOGIC TESTS; INDICATORS AND REAGENTS; INFORMED CONSENT; MALE; MIDDLE AGED; OCCULT BLOOD; PYRUVATE KINASE; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 17444394338     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-865100     Document Type: Article

References (33)

1. Allison JE, Tekawa IS, Ransom LJ, Adrian AL. A comparison of fecal-occult blood tests for colorectal-cancer screening. N Engl J Med 1996; 336: 155-159
2. Australian Health Technology Advisory Committee. Colorectal cancer screening. Cat. No. 9801293 Australian Government Printing Service, 1997
3. Dvorak M, Kocna P, Vanicková Z. Occult fecal blood loss-comparison of immunochemical and biochemical tests. Cas Lék Cesk 2002; 141: 217-219
4. Greenberg PD, Bertario L, Gnauck R et al. A prospective multi-center evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol 2000; 95: 1331-1338
5. Hardcastle JD, Chamberlain JO, Robinson MHE et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-1427
6. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU. Measurement of fecal pyruvate kinase Type M2 (Tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003; 23: 851-854
7. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU, Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening. Anticancer Res 2003; 23: 855-858
8. Hardt PD, Toepler M, Schlierbach P et al. Messung der Tumor M2-Pyruvatkinase als Screening Marker für kolorektale Karzinome. 109. Jahrestagung der Deutschen Gesellschaft für Innere Medizin, Wiesbaden, 2003, Poster. 2003
9. Hardt PD, Mazurek S, Toepler M et al. Faecal tumor M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. B J Cancer 2004: advance online publication
10. Jorgensen OD, Kronborg O, Fenger C. A randomized study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002; 50: 29-32
11. Kronborg O, Fenger C, Olsen J et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-1471
12. Ko CW, Dominitz JA, Nguyen TD. Fecal occult blood testing in a general medical clinic: Comparison between Guaiac-based and immunochemical-based tests. Am J Med 2003; 115: 111-114
13. Levin B, Hess K, Johnson C. Screening for colorectal cancer: A comparison of 3 fecal occult blood tests. Arch Intern Med 1997; 157: 970-976
14. Levin B, Brooks D, Smith RA, Stone A. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin 2003; 53: 44-55
15. Lieberman DA, Weiss DG. One-Time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. New Engl J Med 2001; 345: 555-559
16. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328: 1365-1371
17. Mandel JS, Church TS, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434-437
18. Mandel JS, Church TS, Bond JH et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603-1607
19. Nakama H, Zhang B, Kamijo N. Sensitivity of immunochemical fecal occult blood test for colorectal flat adenomas. Hepatogastroenterology 2004;51:1333-1336
20. Naumann M, Schaum B, Oremek GM, Hanisch E, Rösch W, Mössner J, Caspary WF, Stein J. Pyruvatkinase Typ M2 (M2-PK) im Stuhl - Ein valider Screeningparameter für kolorektale Neoplasien? Dtsch Med Wochenschr 2004; 129: 1806-1807
21. Ontario Expert Panel on Colorectal Cancer Screening. Colorectal cancer in Ontario 1971-1996. Toronto: Cancer Care, 1999
22. Petrelli N, Michalek AM, Freedman A et al. Immunochemical versus guaiac occult blood stool test: Result of a community based screening program. Surg Oncol 1994; 3: 27-36
23. Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 2002; 50: 840-844
24. Smith RA, von Eschenbach A, Wender R et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2001; 51:38-75
25. The European Group for Colorectal Cancer Screening. Recommendations to include colorectal cancer screening in public health policy. J Med Screen 1999; 6: 80-81
26. Towler B, Irwing L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 1998; 317: 559-565
27. Trojan J, Povse N, Schröder O, Stein J. A new immunological test strip device for the rapid, qualitative detection of faecal occult blood. Z Gastroenterol 2002; 40: 921-924
28. U.S. Preventive services task force. Screening for colorectal cancer: Recommendations and rationale. Ann Int Med 2002; 137: 129-131
29. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993; 85: 1311-1318
30. Winawer SJ, Zauber AG, Ho MN et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993; 329: 1977-1981
31. Winawer SJ, Fletcher RH, Miller L et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997; 112: 594-642
32. Winawer SJ, St John DJB, Bond JH et al. Prevention of colorectal cancer: Guidelines based on new data. Bull WHO 1995; 73: 7-10
33. Young GP, St John DJB, Winawer SJ et al. Choice of fecal occult blood tests for colorectal cancer screening: Recommendations based on performance characteristics in population studies. Am J Gastroenterol 2002; 97: 2499-2507